<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02524834</url>
  </required_header>
  <id_info>
    <org_study_id>PSIDE:Thoracoabdominal Lesions</org_study_id>
    <nct_id>NCT02524834</nct_id>
  </id_info>
  <brief_title>Endovascular Repair of Descending ThoracoAbdominal Aortic Pathologies Using Physician Modified Endovascular Prosthesis</brief_title>
  <official_title>Proposed Single Center Investigational Device Exemption: Endovascular Repair of Descending ThoracoAbdominal Aortic Pathologies Using Physician Modified Endovascular Prosthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rodney A. White, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Long Beach Memorial Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an early feasibility study that investigates the outcome of selected patients with&#xD;
      complex thoracoabdominal aortic lesions who are suitable for endovascular (within the vessel)&#xD;
      repair with a physician-modified Medtronic Thoracic Valiant stent graft. The Medtronic&#xD;
      Valiant System includes a Valiant Thoracic Stent Graft, a self-expanding, tubular end&#xD;
      prosthesis which is modified/customized by the Investigators to fit the patient's anatomy.&#xD;
      The device is constructed by making a taper in the larger proximal thoracic device and&#xD;
      attaching it to a smaller distal thoracic device. The Viabahn branches for the visceral&#xD;
      vessels are sutured to holes made in the tapered section. The modified Valiant stent graft is&#xD;
      advanced to the lesion site endoluminally via the iliac/femoral artery. Access for delivery&#xD;
      of extensions to the device will be delivered through the left subclavian artery. Upon&#xD;
      deployment, the stent graft self-expands at the target location, where it is designed to&#xD;
      exclude the lesion by restoring blood flow through the stent graft lumen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted with non-surgical or very high-risk patients who are considered&#xD;
      suitable candidates for endoluminal repair and who are diagnosed with a Type IV complex&#xD;
      thoracoabdominal aortic lesion. The total number of enrolled subjects is planned to be 15. It&#xD;
      is a prospective evaluation of patients receiving the device to determine the proportion in&#xD;
      whom successful implantation is achieved, as indicated by exclusion of the thoracic lesion&#xD;
      and graft patency at implant, time of discharge, and 1, 6, and 12 months following&#xD;
      implantation, and to determine the proportion of patients who die or experience adverse&#xD;
      events during and after the implantation. Furthermore, the percentage of patients in whom&#xD;
      technical and clinical success is achieved, will be determined. Patients will be followed for&#xD;
      5 years after the surgery in which the stent graft is implanted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2030</completion_date>
  <primary_completion_date type="Anticipated">July 2030</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>30 days post intervention</time_frame>
    <description>Early (at 30-days) death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Additional endovascular procedure</measure>
    <time_frame>At 30 days</time_frame>
    <description>Re-intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conversion to open repair</measure>
    <time_frame>At 30 days</time_frame>
    <description>Surgical conversion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>At 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>At 1 year post procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Additional endovascular procedure</measure>
    <time_frame>At 1 year</time_frame>
    <description>Re-intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conversion to open repair</measure>
    <time_frame>At 1 year</time_frame>
    <description>Surgical conversion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vessel complications</measure>
    <time_frame>Up to 5 years post intervention</time_frame>
    <description>Includes dissection, thrombosis, embolization of vessels, malperfusion of branch vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical observations</measure>
    <time_frame>Up to 5 years post intervention</time_frame>
    <description>Includes loss of patency, endoleaks, twisting, kinking, fracture of stent graft, migration and separation of components</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of myocardial infarction, organ failure, sepsis</measure>
    <time_frame>Up tp 5 years post intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Aortic Disease</condition>
  <arm_group>
    <arm_group_label>Endovascular Device Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoluminal exclusion of thoracoabdominal lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Exclusion of thoracoabdominal lesion</intervention_name>
    <description>Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft</description>
    <arm_group_label>Endovascular Device Implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular Device Implant</intervention_name>
    <description>Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft</description>
    <arm_group_label>Endovascular Device Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a Type IV complex thoracoabdominal aortic lesion and be considered&#xD;
             candidates for endovascular repair;&#xD;
&#xD;
          -  Patients must have an ileofemoral access compatible with delivery of a 25 Fr&#xD;
             MedtronicValiant thoracic endograft;&#xD;
&#xD;
          -  Patients must have a left subclavian artery anatomy compatible with 8 mm Dacron&#xD;
             conduit to provide safe, sequential antegrade deployments of branch extensions&#xD;
&#xD;
          -  Patients must have a nonaneurysmal proximal aortic segment distal to the left&#xD;
             subclavian artery with at least 2 cm length to assure secure proximal fixation with a&#xD;
&#xD;
               -  Minimum diameter of 28 mm&#xD;
&#xD;
               -  Maximum diameter of 42mm&#xD;
&#xD;
               -  Angle less than 60° relative to axis of the aneurysm&#xD;
&#xD;
               -  Angle less than 60° relative to axis of the thoracic aorta;&#xD;
&#xD;
          -  Patients must have a distal fixation iliac artery diameter greater than 2 cm in length&#xD;
             and 12-28 mm in diameter;&#xD;
&#xD;
          -  Patients must be high-risk surgical candidates according to the following established&#xD;
             criteria: ASA score of IV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or pediatric patients (younger than 21 years of age);&#xD;
&#xD;
          -  Patients who have a condition that threatens to infect the stent graft/aortic valve&#xD;
             prosthesis;&#xD;
&#xD;
          -  Patients with allergies to the stent graft material;&#xD;
&#xD;
          -  Patients who fail to sign informed consent;&#xD;
&#xD;
          -  Patients with expected survival less than one year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodney A White, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles BioMedical Research Institute, Vascular Surgery and Medical Director, Vascular Surgery Long Beach Memorial Heart &amp; Vascular Institute, Long Beach, CA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rodney A White, MD</last_name>
    <phone>310 963-5230</phone>
    <email>rawhite@ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ankur Gupta, MD</last_name>
    <phone>650- 224-8977</phone>
    <email>agupta2@memorialcare.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center, Memorial Heart &amp; Vascular Institute</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodney A White, MD</last_name>
      <phone>310-963-5230</phone>
      <email>rawhite@ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ankur Gupta, MD</last_name>
      <phone>650 224 8977</phone>
      <email>agupta2@memorialcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ankur Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raffat Jaber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LAC Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodney White, MD</last_name>
      <phone>310-963-5230</phone>
      <email>rawhite@ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Burrola, BS</last_name>
      <phone>310 222-3612</phone>
      <email>lburrola@labiomed.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rodney A White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Archie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</investigator_affiliation>
    <investigator_full_name>Rodney A. White, M.D.</investigator_full_name>
    <investigator_title>Medical Director, Vascular Surgery, Long Beach Memorial Heart &amp; Vascular Institute, Long Beach, CA</investigator_title>
  </responsible_party>
  <keyword>Thoracoabdominal lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

